RXII: Summary for RXi Pharmaceuticals Corporation - Yahoo! Canada Finance

	Sign In [New User? Sign Up]	Finance Home \|Help

Wednesday, February 10, 2010, 6:56am EST - Canadian Markets open in 2 hours and 34 minutes.

To create a watchlist or portfolio of shares, Sign-in or Register

RXi Pharmaceuticals Corporation (RXII)

On Feb 9: 5.35 USD 0.00 (0.00%)

MORE ON RXII

Quotes

Summary

Charts

News & Info

Company

Analyst Coverage

Ownership

Financials

RXi Pharmaceuticals Corporation (NCM:RXII) Delayed quote data

Last Trade:	5.35 USD
Trade Time:	Feb 9
Change:	0.00 (0.00%)
Prev Close:	5.35
Open:	N/A
Bid:	4.60 x 100
Ask:	6.28 x 100
1y Target Est:	15.00

Day's Range:	N/A - N/A
52wk Range:	1.51 - 7.57
Volume:	0
Avg Vol (3m):	180,894
Market Cap:	86.71M
P/E (ttm):	N/A
EPS (ttm):	-1.15
Div & Yield:	N/A (N/A%)

1d 5d 3m 6m 1y 2y

Add RXII to Portfolio

Download Data

HEADLINES

•	RXi Pharmaceuticals to Webcast Presentation at the 12th Annual BIO CEO & Investor Conference
	Business Wire (Mon, Feb 1)

•	Build Your Fortune With These Winners
	at Motley Fool (Thu, Jan 28)

•	RXi Pharmaceuticals Presented New Pre-Clinical Data at the Keystone RNAi Silencing Conference
	Business Wire (Tue, Jan 19)

•	RXi Pharmaceuticals Talks Partnerships
	at Seeking Alpha (Sat, Jan 16)

•	"Buyout in the Works" After NWCI is Awarded Key Patent
	BayStreet Newswire (Fri, Jan 15)

•	RXi Pharmaceuticals and the University of Massachusetts Medical School Announce Research Collaboration Focused on Ocular Disease
	Business Wire (Thu, Jan 14)

•	RXi Pharmaceuticals to Webcast Presentation at the Biotech Showcase Conference
	Business Wire (Thu, Jan 7)

•	Coverage initiated on RXi Pharmaceuticals by Rodman & Renshaw
	Briefing.com (Mon, Dec 21)

•	RXi Pharmaceuticals Corp.: Warming Up or Cooling Off?
	at Motley Fool (Tue, Dec 1)

•	Three Lou Gehrigs Disease (ALS) Organizations Grant Funding for Research Collaboration Between RXi Pharmaceuticals and UMass Medical School
	Business Wire (Mon, Nov 30)

•	RXi Pharmaceuticals Wins 2009 RNAi Technology Innovation of the Year Award from Frost & Sullivan
	Business Wire (Mon, Nov 23)

More Headlines for RXII...

ANALYST

EPS Est (next year) (Dec-09) :	-1.12
EPS Est (in 2 years) (Dec-10) :	-0.95
Avg Rec (current)*:	1.0
PEG Ratio:	N/A

* (Strong Buy) 1.0 - 5.0 (Strong Sell)

Analyst Opinion - Estimates

BUSINESS SUMMARY

RXi Pharmaceuticals Corporation, a discovery-stage biopharmaceutical company, focuses on the development and commercialization of proprietary therapeutics based on RNA interference for the treatment of human diseases in the United States and inter...

Full Company Profile

Add to Portfolio

Email to a Friend

•